MiMedx Group’s (MDXG) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of MiMedx Group (NASDAQ:MDXG) in a report published on Thursday morning,Benzinga reports. Cantor Fitzgerald currently has a $13.00 price objective on the stock.

Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Trading Up 3.2 %

Shares of MiMedx Group stock opened at $8.40 on Thursday. The business has a fifty day simple moving average of $8.72 and a two-hundred day simple moving average of $7.71. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of 15.27 and a beta of 1.94. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. Research analysts forecast that MiMedx Group will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. IMG Wealth Management Inc. bought a new position in shares of MiMedx Group in the fourth quarter worth $28,000. Blue Trust Inc. bought a new position in shares of MiMedx Group in the third quarter worth $30,000. Virtus Fund Advisers LLC bought a new position in shares of MiMedx Group in the fourth quarter worth $35,000. Van ECK Associates Corp bought a new position in shares of MiMedx Group in the fourth quarter worth $40,000. Finally, Point72 DIFC Ltd increased its position in shares of MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after purchasing an additional 4,275 shares during the period. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.